The Claim
Combination therapy with photodynamic therapy and anti-VEGF agents reduces the number of required anti-VEGF injections compared to monotherapy in treatment-naïve polypoidal choroidal vasculopathy patients.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with anti-VEGF injections results in fewer anti-VEGF injections over time than using anti-VEGF injections alone.
See the scientific wording
Combination therapy with photodynamic therapy and anti-VEGF agents reduces the number of required anti-VEGF injections compared to monotherapy in treatment-naïve polypoidal choroidal vasculopathy patients, suggesting a potential reduction in treatment burden and associated risks.
The light treatment damages abnormal blood vessels in the eye, making them less leaky and more stable. This reduces the need for ongoing injections that block a protein causing vessel leakage and growth.
What the research says
1 studyPatients with this eye condition who get both a special light treatment and eye injections need fewer injections over time than those who only get injections, meaning fewer doctor visits and less risk. The study proves this combo works better and is safer.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.